Jazz Pharmaceutical join growing medical cannabinoid industry

Yesterday Jazz Pharmaceutical (JAZZ.OQ) announced a £5.3B deal to takeover Cambridge based GW pharmaceuticals. Jazz currently has a wide portfolio of drugs focused on sleep, haematology and oncology therapies. This acquisition will add GW’s epilepsy drug Epidolex and MS drug to their portfolio but more excitingly it gives them access to the largest infrastructure for the production and processing of medical cannabis in the UK, one of the worlds largest exporters of cannabis-derived medicines

The medical cannabis market is expected to grow significantly over the next 5-10 years as more countries around the world start to […]